↑Degner, Lesley F.; Sloan, Jeffrey A. (1995). "Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer". Journal of Pain and Symptom Management. 10 (6): 423–431. doi:10.1016/0885-3924(95)00056-5. ISSN0885-3924.
↑Feinstein AR, Wells CK (1990). "A clinical-severity staging system for patients with lung cancer". Medicine (Baltimore). 69 (1): 1–33. PMID2299974.
↑Chute CG, Greenberg ER, Baron J, Korson R, Baker J, Yates J (1985). "Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont". Cancer. 56 (8): 2107–11. PMID2992757.
↑Hirshberg B, Biran I, Glazer M, Kramer MR (1997). "Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital". Chest. 112 (2): 440–4. PMID9266882.
↑Kuo CW, Chen YM, Chao JY, Tsai CM, Perng RP (2000). "Non-small cell lung cancer in very young and very old patients". Chest. 117 (2): 354–7. PMID10669674.
↑Lepper PM, Ott SR, Hoppe H, Schumann C, Stammberger U, Bugalho A, Frese S, Schmücking M, Blumstein NM, Diehm N, Bals R, Hamacher J (2011). "Superior vena cava syndrome in thoracic malignancies". Respir Care. 56 (5): 653–66. doi:10.4187/respcare.00947. PMID21276318.
↑Buccheri, G. (2004). "Lung cancer: clinical presentation and specialist referral time". European Respiratory Journal. 24 (6): 898–904. doi:10.1183/09031936.04.00113603. ISSN0903-1936.